BioMedNewsBreaks

WednesdayMay 19, 2021 9:57 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Patient Enrollment in Berubicin Study

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has begun open enrollment for its upcoming study focused on analyzing the efficacy and safety of Berubicin in the treatment of adult recurrent Glioblastoma Multiforme (“GBM”). GMB is one of the most aggressive types of brain cancer, and Berubicin, which is in development for the treatment of several serious brain and CNS oncology indications, is the first anthracycline to cross the blood-brain barrier. CNSP plans on enrolling some 210 subjects across 35 clinical sites…

Continue Reading

TuesdayMay 18, 2021 3:13 pm

BioMedNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Helomics CTO Discusses Revolutionizing Drug Discovery in Bell2Bell Podcast

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, was featured in a recent episode of The Bell2Bell Podcast. Predictive Oncology’s newly appointed CEO Mel Engle, CFO Bob Myers and Mark Collins, chief technical officer of the company’s Helomics subsidiary, joined the program to share financial updates, future goals and insight into current operations. The discussion also highlighted Helomics’ innovative PeDAL (patient-centric drug discovery using active learning) platform. A unique technology, PeDAL combines a proprietary, clinically validated patient tumor cell line assay with a vast knowledge base of proprietary and…

Continue Reading

TuesdayMay 18, 2021 2:59 pm

BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Eyes ‘Exceptional’ Work to Move i/Blue Imaging System(TM) into Commercial Manufacturing

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, was featured in a recent article that discussed its timely progress toward 2022 completion of its innovative i/Blue Imaging System(TM). The patented system is designed leveraging proprietary light sensors and optics to improve the efficiency and accuracy of bladder cancer visualization and removal. According to the update, the on-track progress can be largely attributed to the company’s selection of Lighthouse Imaging as its manufacturing partner. “Lighthouse’s development program is focused on refining the i/Blue system’s design to ensure that the final device complies with all regulatory standards while maintaining optimal…

Continue Reading

FridayMay 14, 2021 1:35 pm

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Focuses ‘Covid-ID Lab’ Commercialization Strategy Initially on German Market

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, recently entered a strategic distribution, storage and logistics agreement for its commercial 25-minute COVID-19 RT-PCR test system (“Covid-ID Lab”). In April, XPhyto announced its entry into the agreement with a full-fledged German pharmaceutical wholesaler and service provider. Under the agreement, the German partner will distribute, store and deliver Covid-ID Lab test kits to XPhyto’s customers in line with product specifications and relevant logistical and regulatory requirements in Germany. A recent article quotes XPhyto CEO and Director Hugh Rogers, who noted that the company had secured a strong partner…

Continue Reading

FridayMay 14, 2021 12:38 pm

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Collaborating to Potentially Uncover Innovative New Treatment Options

Brain Scientific (OTCQB: BRSF), focused on modernizing the brain diagnostic market through cutting-edge technologies, recently began a collaboration with JelikaLite in a clinical trial. The clinical trial, which has 30 participants from two New York City locations, is designed to potentially uncover new treatment options to reduce autism symptoms in children. “JelikaLite was launched by medical researchers and practitioners specializing in psychology, neurology and phototherapy. The company has developed an innovative solution to potentially reduce autism symptoms and is developing a home-based system that combines a therapeutic wearable device called Cognilum(TM) with an AI-personalized platform. . . Cognilum delivers treatments…

Continue Reading

FridayMay 14, 2021 10:57 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q1 2021 Results, Provides Clinical Update and Business Outlook

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today provided a clinical update and business outlook and released its financial results for the quarter ended March 31, 2021. "2021 is poised to be an exciting year for the company. Throughout the first quarter, we have made continued development and regulatory progress on all fronts and are committed to driving our novel treatments forward as expeditiously as possible with the primary focus on our Berubicin program to improve patient outcomes for GBM," said…

Continue Reading

FridayMay 14, 2021 10:54 am

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Q1 2021 Financial, Corporate Report

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, has reported its financial and corporate results for the first quarter of 2021, the period ended March 31, 2021. In the report, PCSA noted that its clinical drug pipeline is funded and targeting major milestones throughout this year. Corporate highlights for the company included the selection of five clinical sites around the United States for the upcoming phase 2b randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of PCS499 in treating patients who…

Continue Reading

FridayMay 14, 2021 9:36 am

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) CEO Shares Six Keys to Leadership Growth in “Forbes” Article

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) CEO Greg McKee was featured in a recent “Forbes” article touting six keys to leadership growth. In the article, McKee shared valuable insight into the most effective ways that leaders can grow and develop. The behaviors McKee encouraged include staying curious and stepping outside of your comfort zone as well as not waiting for experiences and making experiences as you go. McKee also urged potential leaders to never stop learning and, in fact, noted that they could learn from every experience. McKee also encouraged leaders to not be afraid of breaking with convention.…

Continue Reading

ThursdayMay 13, 2021 11:49 am

BioMedNewsBreaks – RYAH Group Inc.’s (CSE: RYAH) RYAH Medtech Expands Business Development Team

RYAH Group’s (CSE: RYAH) wholly owned subsidiary, RYAH Medtech Inc., has welcomed four new members to its business development team, namely Steven Schultz, Warren Thompson, Mitchell Zimmer, and Andrea Ferrari. According to the update, the newly added experts bring extensive experience and expertise in the medical and pharmaceutical industry. The team will focus on expanding RYAH’s presence in multiple verticals within the North America plant-based and nutraceutical markets, including participation in clinical trials for the company’s connected devices and custom software solutions in data analytics. “We are thrilled to announce these new appointments. This team has deep acumen in the medical…

Continue Reading

ThursdayMay 13, 2021 10:26 am

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Releases Business, Drug-Development Status

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, released an update on its 2021 drug formulation programs, noting that the programs are advancing on schedule and expanding in scope. The company’s Rotigotine transdermal human pilot study was successfully completed in March and the program now advancing to a pivotal study stage; the pilot study evaluated the use of the Rotigotine transdermal patch in the treatment for Parkinson's disease. In addition, the update noted that XPhyto had purchased land in Germany for the construction of its commercial drug manufacturing facility in…

Continue Reading